UAB Enrolling New Trial for Testing Verapamil as Potential Cure for Diabetes10:44 AM
|Pancreas beta cells produce insulin, helping the body|
process blood sugar. Damaged beta cells are unable
to produce insulin at the needed rate, resulting in
excessively high levels of blood sugar, and diabetes.
In mice studies at UAB, Verapamil was used to reduce the amount of TXNIP proteins within the pancreas beta cells, effectively "reversing" diabetic damage to the pancreas and preserving beta cell function. They report that diabetes "was eradicated" in the treated mice who had blood sugar levels above 300 mg/deciliter.
Since the safety of Verapmil for human use has been verified by its previous uses on the market as a blood pressure treatment, UAB is set to enroll its first human study to begin testing its effects on human pancreas beta cells. Enrollment is set to begin in early 2015, and UAB researchers are looking for patients aged 19 to 45 with type 1 diabetes. The study will run over one year and will compare Verapamil versus placebo in a randomized distribution. Insulin pumps will be used as directed throughout the study for both groups and a continuous glucose monitoring device will be used to accurately report hourly readings of sugar levels.
|Non Proliferative diabetic retinopathy|
For more information concerning the UAB study or to enroll, contact Kentress Davison at 205-934-4112 or 205-975-9308.